Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ALXN2050 on QT Interval in Healthy Adults
NCT04660890Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Placebo-corrected Change From Baseline QTc Intervals. Started Dec 2020; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04660890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660890.